Sia Anagnostou, Senior Director of Corporate Development at Immunomic Therapeutics, Inc. (ITI), is responsible for several core areas including alliance development and portfolio management. Anagnostou directs ITI branding initiatives and communications to raise awareness about ITI with important stakeholders in the science, government and investment communities.  In concert with research and development, she advances collaborations and licensing opportunities, manages assessments and transactions, and integrates results into ITI’s business strategy.

Mrs. Anagnostou has been a member of ITI’s staff since 2012 and previously worked with Theranostics Health, where she focused on cancer proteomic molecular diagnostics. She earned her executive M.B.A. from Duke University, her Master of Science in Molecular Biology from Georgetown University Medical School, and her B.S. in Foreign Service from Georgetown University.